Published: Jan. 19, 2022 at 8:09 a.m. ET By Chris Wack Immix Biopharma Inc. said it saw positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. The company said that historically, 43% to 67% […]
Jan. 19, 2022 9:13 AM ET Immix Biopharma, Inc. (IMMX) By: Dulan Lokuwithana, SA News Editor – Immix Biopharma (NASDAQ:IMMX) is trading ~3.6% higher after announcing 100% completion of planned treatment cycles in an ongoing Phase 1b/2a clinical trial for IMX-110, its candidate for soft tissue […]
January 4, 2022Kristi Rosa The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma. The FDA has granted a rare pediatric disease designation (RPDD) to IMX-110 for the treatment of rhabdomyosarcoma, according to an announcement from Immix Biopharma, Inc., the […]
Pre-market Movers: IMMX… ContributorRTTNews.com RTTNews PublishedJan 4, 2022 7:33AM EST (RTTNews) – The following are some of the stocks making big moves in Tuesday’s pre-market trading (as of 07.20 A.M. ET). In the Green Immix Biopharma, Inc. (IMMX) is up over 18% at $6.85… Original Article […]
EXCLUSIVE: Immix CEO On ‘Benzinga Live’ Adam Eckert , Benzinga Staff Writer January 03, 2022 3:05pm Immix Biopharma Inc IMMX +62.36% stock is soaring Monday after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening […]
Reuters January 3, 2022 9:40 AM PST Reuters** Immix Biopharma Inc (IMMX.O): up 109.3% BUZZ-Immix Biopharma jumps on rare-disease tag for pediatric cancer drug Original Article Link
Jan. 03, 2022 8:46 AM ET Immix Biopharma, Inc. (IMMX) By: Dulan Lokuwithana, SA News Editor – Immix Biopharma (NASDAQ:IMMX) has jumped ~56.7% in the pre-market on above average volume after the company announced that the FDA granted the Rare Pediatric Disease (RPD) designation for IMX-110, […]
Published: Jan. 3, 2022 at 12:03 p.m. ETBy Colin Kellaher Shares of Immix Biopharma Inc. more than doubled on Monday after the biopharmaceutical company’s lead product candidate received rare-pediatric-disease designation from the U.S. Food and Drug Administration. The Los Angeles company said the designation covers IMX-110 […]
Seeking Alpha / Avisol Capital Partners Sep. 28, 2021 2:12 PM ET Immix Biopharma, Inc. (IMMX) Summary Immix Biopharma is developing Tissue-Specific Therapeutics in oncology and inflammation with a Tumor Micro-Environment Normalization technology.The Company’s lead candidate has shown promising results in ongoing Phase 1b/2a trials.The Company […]
Renaissance Capital September 17, 2021 Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, filed on Friday with the SEC to raise up to $25 million in an initial public offering. Immix is developing a novel class of Tissue-Specific Therapeutics (“TSTx”) in oncology […]
Fortune September 17, 2021 “Immix Biopharma, a Los Angeles-based oncology drug company, filed for an initial public offering …” Original Article Link
Seeking Alpha Aug. 27, 2021 8:47 AM ET By: Aakash Babu, SA News Editor     BeiGene (NASDAQ:BGNE) and Immix Biopharma announce a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a combination of IMX-110 and tislelizumab for the treatment of various […]
Seeking Alpha Jul. 23, 2021 11:11 AM ET By: Jonathan M Block, SA News Editor Immix Biopharma has confidentially submitted a draft registration statement (S-1 form) for an initial public offering. The number of shares to be offered and the share price range have yet to […]
dot.la Keerthi Vedantam 03:52 PM | July 23, 2021 ImmixBio, a West L.A.-based startup developing cancer therapies, announced on Friday it submitted a confidential filing to go public. Ilya Rachman, chief executive of the nine-year-old company which has developed a combination therapy meant to prevent cancers […]
FierceBiotech Jul 9, 2021 9:30am “Immix Bio, focused on tissue-specific therapeutics for oncology and inflammation, chose Gabriel Morris as its chief financial officer and board member.” Original Article Link